Directed new share issue in Clavis Pharma ASA (NO) — NOK 163 million

Carnegie acted as joint book-runner in the directed new share issue of 2.86 million shares at a subscription price of NOK 57.00 per share. Clavis Pharma ASA is a clinical stage oncology discovery and drug development company, with a portfolio of novel anti-cancer drugs in development. January, 2012.